FATE News and Press, Fate Therapeutics Inc. From 09/20/23

2023-09-20 11:55:57 ET More on Health Care Sector: Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Health Care Select Sector SPDR ETF declares quarterly distribution of $0.5395 BofA clients were net buyers of U.S. equities for a fifth consecutiv...

Fate Therapeutics, Inc. (NASDAQ: FATE) is one of today's top gainers. The company's shares are currently up 11.14% on the day to $2.44. Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. I...

2023-09-13 17:07:09 ET Gainers: The Kraft Heinz  ( KHC ) +6% . CareDx ( CDNA ) +5% . Payoneer Global ( PAYO ) +5% . Microvast Holdings ( MVST ) +4% . Fate Therapeutics ( FATE ) +4% . Losers: IBEX Limited ( IBEX )...

2023-09-01 10:00:10 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) Tech Ruled The First Half Of 2023, The Industry You Need To Watch In The Second Half XLV Vs. VHT: A Head-To-Head Healthcare ETF C...

SAN DIEGO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellul...

2023-08-28 17:17:30 ET Gainers: Fate Therapeutics ( NASDAQ: FATE ) +5% . Diversified Healthcare  ( DHC ) +4% . Taysha Gene Therapies ( TSHA ) +3% . Afya ( AFYA ) +3% . Iris Energy ( IREN ) +2% . Losers: Kodiak Sc...

2023-08-16 09:05:49 ET Summary Fate Therapeutics is a cell therapy company focused on CAR-T and NK cells for autoimmune diseases and cancer. Their product candidates are still in early clinical trials or preclinical stages, making their path forward uncertain. The company has ...

2023-08-08 23:37:12 ET Fate Therapeutics, Inc. (FATE) Q2 2023 Earnings Conference Call August 8, 2023 17:00 ET Company Participants Scott Wolchko - President & Chief Executive Officer Ed Dulac - Chief Financial Officer Bob Valamehr - Chief Research & Deve...

2023-08-08 16:16:44 ET Fate Therapeutics press release ( NASDAQ: FATE ): Q2 GAAP EPS of -$0.54 beats by $0.06 . Revenue of $0.93M (-95.0% Y/Y) misses by $4.81M . For further details see: Fate Therapeutics GAAP EPS of -$0.54 beats by $0.06, revenue of $0.9...

Phase 1 Study Start-up Ongoing for FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Conditioning Chemotherapy 2H23 IND Submission Planned under ONO Collaboration for FT825/ONO-8250; HER2-t...